TrialJapanese journal of clinical oncology2024

Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.

Shinsuke Iida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.